Maxcyte (MXCT) Operating Leases (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Leases data on file, last reported at $16.1 million in Q1 2026.

• Quarterly Operating Leases fell 8.17% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (down 8.17% YoY) and the FY2025 annual result came in at $16.5 million, down 3.98% from the prior year.
• Operating Leases slipped to $16.1 million in Q1 2026 per MXCT's latest filing, from $16.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $18.0 million in Q4 2023 and bottomed at $12.8 million in Q1 2022.
• The 5-year median for Operating Leases is $16.5 million (2025), against an average of $16.3 million.
• The widest annual swing landed in 2022, when Operating Leases surged 2873.17%; it then retreated 8.17% in 2026.
• Tracing MXCT's Operating Leases over 5 years: stood at $15.9 million in 2022, then grew by 12.74% to $18.0 million in 2023, then slipped by 4.45% to $17.2 million in 2024, then fell by 3.98% to $16.5 million in 2025, then fell by 2.27% to $16.1 million in 2026.
• Per Business Quant, the three latest MXCT Operating Leases figures stand at $16.1 million (Q1 2026), $16.5 million (Q4 2025), and $16.8 million (Q3 2025).

Peer Comparison